SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2021 / Cilt: 5 - Sayı: 3

B-RAF V600E AND B-RAF CODON 464-469 MUTATIONS IN HAIRY CELL LEUKEMIA PATIENTS AND THEIR RELATION WITH CLINICAL PARAMETERS

Mahdi AKBARPOUR
Aybuke OLGUN
Yasemin BASBINAR
Inci ALACACIOGLU
Serife SOLMAZ
Ozlem BIRGE
Hulya ELLIDOKUZ
Tugba UYSAL KILIC
Pages
1–6
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also it can be used as a marker to select the candidate patients for target therapies, who did not respond to the conventional therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder which counts %2-3 percent of the leukemias.
📊
Key Findings & Data:The most common B-RAF mutation V600E has been shown in hairy cell leukemia recently.
💡
Conclusion & Impact:Also it can be used as a marker to select the candidate patients for target therapies, who did not respond to the conventional therapies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HAIRY CELL LEUKEMIA · B-RAF V600E · B-RAF G464E

Abstract

PURPOSE: Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder which counts %2-3 percent of the leukemias. B-RAF is a member of mitogen activated protein kinase pathway, associated with cell proliferation. The most common B-RAF mutation V600E has been shown in hairy cell leukemia recently. The aim of our study is to investigate B-RAF V600E and B-RAF codon 464-469 mutations in HCL patients and compare the results with clinical parameters. METHODS: Thirteen individuals who were diagnosed and followed up with hairy cell leukemia in Dokuz Eylul University Faculty of Medicine Hematology outpatient clinic are included in our study. Demographic and clinical data are collected and B-RAF mutations are analyzed with pyrosequencing based molecular methods. RESULTS: B-RAFV600E mutation was positive in 10 (%76,9) patients. B-RAF G464E was mutated in one patient, B-RAF G466E was positive in another and B-RAF G469E mutation has been found in a patient. Two patients had both codon 600 and codon 464-469 mutations, showing no invincible difference clinically. All the patients having lymphadenopathy had B-RAFV600E mutations.(p=1.000) Response rates were similar in the groups having B-RAFV600E mutation and/or B-RAF codon 464-469 mutations. CONCLUSION: B-RAF is a commonly mutated gene in hairy cell leukemia with different types of muatations. Especially B-RAFV600E mutation can be used as a supportive diagnostic test, in cases with contraversial diagnosis or differential diagnosis of other peripheral B cell neoplasms. Also it can be used as a marker to select the candidate patients for target therapies, who did not respond to the conventional therapies.

🔖

Cite This Article

AKBARPOUR, M., OLGUN, A., BASBINAR, Y., ALACACIOGLU, I., SOLMAZ, S., BIRGE, O., ELLIDOKUZ, H., KILIC, T. U. (2022). B-RAF V600E AND B-RAF CODON 464-469 MUTATIONS IN HAIRY CELL LEUKEMIA PATIENTS AND THEIR RELATION WITH CLINICAL PARAMETERS. Journal of Basic and Clinical Health Sciences, Cilt: 5 - Sayı: 3, 1–6. https://ajindex.com/articles/560483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic Reticuloendotheliosis. Blood. 1958; 13(7): 609–30
  2. Schrek R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood 1966; 27(2): 199–211
  3. Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, et al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. JNCI Monogr 2014; 2014(48): 1–14
  4. Hoffman M a. Clinical Presentations and Complications of Hairy Cell Leukemia. Hematol Oncol Clin North Am. 2006; 20(5): 1065–73
  5. Kraut E. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16(1): 33–40
  6. Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104(11): 2442–8
  7. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZS, Johnson S a N, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145(6): 733–40
  8. Tiacci E, Trifonov V, Ph D, Schiavoni G, Holmes A, Kern W, et al. Braf mutations in hairy cell leukemia. N Engl J Med. 2011; 364(24): 2305–15
  9. Roskoski R. RAF protein-serine/threonine kinases: Structure and regulation. Biochem Biophys Res Commun 2010; 399(3): 313–7
  10. Cantwell-Dorris E, O’Leary J, Sheils O. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10(3): 385–94
  11. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. 2012; 156(2): 186–95
  12. Polliack A. Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol. 2002; 6(4): 366–88
  13. Dearden C, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 2011; 52(2): 21–4
  14. Goodman GR. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine. J Clin Oncol 2003; 21(5): 891–6
  15. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, et al. Long-term follow-up of remission duration, mortality, and second malignanc